Journal Browser Advanced Search Help
Journal Browser Advanced search HELP
Korean J Anesthesiol. 2011 May;60(5):351-356. English. Original Article.
Kim JH , Jang YH , Chun KJ , Kim J , Park YH , Kim JS , Kim JM , Lee MY .
Institute of Cardiovascular Research Center, Pusan National University Yangsan Hospital, Yangsan, Korea.
Department of Anesthesiology, Pureun Hospital, Daegu, Korea.
Institute for Medical Science, Keimyung University, Daegu, Korea.

BACKGROUND: We investigated whether p42/p44 extracellular signal-regulated kinases (ERK1/2) and/or phosphatidylinositol-3-OH kinase (PI3K)-Akt play a crucial role in cardioprotection by kappa-opioid receptor (KOP) activation. METHODS: Langendorff perfused rat hearts were subjected to 30 min of regional ischemia and 2 h of reperfusion. Antagonists of ERK1/2 and PI3K were perfused in hearts treated with the KOP agonist U50488H (U50). Infarct size was measured after 2 h of reperfusion. The phosphorylation states of ERK1/2 and Akt by Western immunoblots were determined. Drugs were perfused for a period of 5 min before and 30 min after reperfusion. RESULTS: Inhibition of ERK1/2 (26.8 +/- 2.9%, P < 0.05 vs. U50) but not PI3K (15.5 +/- 1.1%, P > 0.05 vs. U50) completely abrogated the anti-infarct effect of U50488H. Western blot analysis revealed a significant increase in ERK1/2 but not Akt phsophorylation in U50488H-treated hearts as compared to control hearts when measured immediately after reperfusion. CONCLUSIONS: KOP activation effectively reduces myocardial infarction. The anti-infarct effect of U50488H is mediated by the ERK1/2, but not the PI3K-Akt pathway.

Copyright © 2019. Korean Association of Medical Journal Editors.